Therapeutic targets of hypercholesterolemia: HMGCR and LDLR

Cholesterol homeostasis is critical and necessary for the body’s functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low–density lipoprotein cholesterol receptor (LDLR) are major...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shizhan, Sun, Wenxiu, Gao, Ling, Liu, Shudong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709517/
https://www.ncbi.nlm.nih.gov/pubmed/31686875
http://dx.doi.org/10.2147/DMSO.S219013
_version_ 1783446211885268992
author Ma, Shizhan
Sun, Wenxiu
Gao, Ling
Liu, Shudong
author_facet Ma, Shizhan
Sun, Wenxiu
Gao, Ling
Liu, Shudong
author_sort Ma, Shizhan
collection PubMed
description Cholesterol homeostasis is critical and necessary for the body’s functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low–density lipoprotein cholesterol receptor (LDLR) are major points of control in cholesterol homeostasis. We summarize the regulatory mechanisms of HMGCR and LDLR, which may provide insight for new drug design and development.
format Online
Article
Text
id pubmed-6709517
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67095172019-11-04 Therapeutic targets of hypercholesterolemia: HMGCR and LDLR Ma, Shizhan Sun, Wenxiu Gao, Ling Liu, Shudong Diabetes Metab Syndr Obes Review Cholesterol homeostasis is critical and necessary for the body’s functions. Hypercholesterolemia can lead to significant clinical problems, such as cardiovascular disease (CVD). 3-Hydroxy-3-methylglutaryl coenzyme A reductase (HMGCR) and low–density lipoprotein cholesterol receptor (LDLR) are major points of control in cholesterol homeostasis. We summarize the regulatory mechanisms of HMGCR and LDLR, which may provide insight for new drug design and development. Dove 2019-08-21 /pmc/articles/PMC6709517/ /pubmed/31686875 http://dx.doi.org/10.2147/DMSO.S219013 Text en © 2019 Ma et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Ma, Shizhan
Sun, Wenxiu
Gao, Ling
Liu, Shudong
Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
title Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
title_full Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
title_fullStr Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
title_full_unstemmed Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
title_short Therapeutic targets of hypercholesterolemia: HMGCR and LDLR
title_sort therapeutic targets of hypercholesterolemia: hmgcr and ldlr
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6709517/
https://www.ncbi.nlm.nih.gov/pubmed/31686875
http://dx.doi.org/10.2147/DMSO.S219013
work_keys_str_mv AT mashizhan therapeutictargetsofhypercholesterolemiahmgcrandldlr
AT sunwenxiu therapeutictargetsofhypercholesterolemiahmgcrandldlr
AT gaoling therapeutictargetsofhypercholesterolemiahmgcrandldlr
AT liushudong therapeutictargetsofhypercholesterolemiahmgcrandldlr

Ejemplares similares